Gladstone Institutional Advisory LLC Boosts Stake in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT)

Gladstone Institutional Advisory LLC boosted its holdings in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) by 75.4% in the fourth quarter, HoldingsChannel.com reports. The firm owned 61,399 shares of the company’s stock after buying an additional 26,399 shares during the quarter. Gladstone Institutional Advisory LLC’s holdings in Checkpoint Therapeutics were worth $196,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Bartlett & CO. Wealth Management LLC grew its holdings in Checkpoint Therapeutics by 375.0% in the 4th quarter. Bartlett & CO. Wealth Management LLC now owns 19,000 shares of the company’s stock valued at $61,000 after buying an additional 15,000 shares during the period. HB Wealth Management LLC grew its holdings in Checkpoint Therapeutics by 96.9% in the 4th quarter. HB Wealth Management LLC now owns 153,560 shares of the company’s stock worth $513,000 after buying an additional 75,560 shares in the last quarter. PVG Asset Management Corp lifted its holdings in shares of Checkpoint Therapeutics by 9.2% in the third quarter. PVG Asset Management Corp now owns 149,870 shares of the company’s stock valued at $336,000 after buying an additional 12,676 shares during the period. Virtu Financial LLC acquired a new stake in Checkpoint Therapeutics during the 3rd quarter worth about $30,000. Finally, Geode Capital Management LLC grew its stake in Checkpoint Therapeutics by 41.2% during the 3rd quarter. Geode Capital Management LLC now owns 427,651 shares of the company’s stock valued at $958,000 after acquiring an additional 124,787 shares in the last quarter. Institutional investors and hedge funds own 22.00% of the company’s stock.

Insiders Place Their Bets

In other Checkpoint Therapeutics news, CFO William Garrett Gray sold 268,432 shares of the firm’s stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $4.01, for a total transaction of $1,076,412.32. Following the sale, the chief financial officer now owns 1,032,754 shares in the company, valued at $4,141,343.54. This trade represents a 20.63 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO James F. Oliviero III sold 9,233 shares of the firm’s stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $3.41, for a total value of $31,484.53. Following the transaction, the chief executive officer now directly owns 3,785,350 shares in the company, valued at $12,908,043.50. This trade represents a 0.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 582,336 shares of company stock valued at $2,156,801. Corporate insiders own 2.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on CKPT shares. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Checkpoint Therapeutics in a research report on Monday, December 16th. Lake Street Capital boosted their price target on shares of Checkpoint Therapeutics from $4.00 to $7.00 and gave the company a “buy” rating in a report on Monday, December 16th. Finally, D. Boral Capital started coverage on Checkpoint Therapeutics in a research report on Monday, January 13th. They set a “buy” rating and a $9.00 price objective for the company.

Checkpoint Therapeutics Trading Down 4.3 %

NASDAQ CKPT opened at $3.31 on Monday. The business’s 50-day moving average price is $3.35 and its two-hundred day moving average price is $3.01. Checkpoint Therapeutics, Inc. has a 12 month low of $1.38 and a 12 month high of $4.50. The firm has a market capitalization of $161.63 million, a PE ratio of -1.80 and a beta of 1.36.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.